Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02070393
Other study ID # IUHPTC-01
Secondary ID
Status Terminated
Phase Phase 0
First received April 19, 2012
Last updated February 3, 2015
Start date September 2011
Est. completion date February 2015

Study information

Verified date February 2015
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to drastically reduce unnecessary breast dose in young females with Hodgkin's Disease who require radiation therapy.


Description:

According to the National Cancer Institute's Surveillance, Epidemiology, and End Results Program, there will be an estimated 8,490 new cases of Hodgkin's Lymphoma (HL) in the United States in 2010, with an estimated 1,320 deaths (Jemal, Siegel et al.). The unadjusted rates of 5 year overall survival are approximately 95%, and remain among the highest of all childhood and adult malignancies. With many children and young adults surviving into advanced age, the impetus has been to develop less toxic yet equally effective treatments. One of the main approaches taken over the last 25 years to minimize long-term treatment toxicity has been to limit the amount and volume of radiation received by patients. This pilot study continues along those lines, attempting to further refine the delivery of radiation therapy (RT) in order to avoid one of the most notorious long-term side-effects: secondary breast cancer.

Multiple studies investigating late toxicity in long-term survivors of pediatric Hodgkin's Lymphoma have shown the risk of breast cancer in young females receiving mediastinal radiation to be 50 times greater than their age-matched counterparts. The Late Effects Study Group, with a median follow-up of 17 years, reported a breast cancer incidence of 16% with a standardized incidence ratio of 55.5 (Bhatia, Yasui et al. 2003). Through utilization of breast-sparing proton therapy, we hope to provide young female patients with the benefits of radiation therapy while decreasing their risk of secondary breast cancer, thus increasing the therapeutic ratio.

In a prior computer-based, in-silico, dose planning study, utilizing the most basic beam orientation (a single PA beam), we showed that dose to breast tissue was reduced by a minimum of at least 80% with proton treatment compared to standard AP-PA photon treatment (in publication). Furthermore, dose to clinical target volume was maintained, and dose to other normal structures was statistically no worse. We now aim to validate these findings by verifying the beam range, in-vivo, via post-treatment combined Positron Emission Tomography-Computer Tomography (PET-CT) imaging in young females undergoing supra-diaphragmatic radiotherapy for Hodgkin's Disease.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date February 2015
Est. primary completion date February 2015
Accepts healthy volunteers No
Gender Female
Age group 10 Years to 30 Years
Eligibility Inclusion Criteria:

- Female sex

- Age >/= 10 years old and < 30 years old

- Pathologically confirmed classical Hodgkin's Lymphoma

- At least one site of disease located above the diaphragm

- Signed study-specific consent prior to initiation of therapy

- Women of child-bearing potential must have a negative pregnancy blood test within 7 days of starting protocol therapy.

Exclusion Criteria:

- Previous radiation therapy to any part of the body.

- Parenchymal lung involvement at initial presentation or any patient that may need whole lung irradiation as per institutional guidelines.

- Lymphocyte predominant histology not eligible.

- Significant infection or other coexistent medical condition that would preclude protocol therapy such as:

- History of HIV/AIDS

- History of collagen Vascular Disease

- Symptomatic congestive heart failure

- Unstable angina pectoris or myocardial infarction within 6 months

- Uncontrolled hypertension (systolic blood pressure > 160 mm Hg or diastolic blood pressure > 100 mm Hg on 2 consecutive measurements separated by 1 week).

- History of uncontrolled diabetes

- Psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Radiation:
Proton
14-24 Radiation treatments using Protons

Locations

Country Name City State
United States Indiana University Health Proton Therapy Center Bloomington Indiana

Sponsors (1)

Lead Sponsor Collaborator
Indiana University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparative DVH data for delivered proton plan and accompanying photon plan for target volume and normal tissues. Dose-volume histogram data from both the delivered proton plan and the accompanying photon plan for target volumes and normal tissues, including:
• Breast, heart, lung, thyroid, parotid glands , esophagus, spinal cord, *liver, *kidneys,
12 months Yes
Secondary Treatment toxicity and disease control of proton therapy for the treatment of pediatric Hodgkin's Lymphoma. Acute toxicity as per CTCAE v4.0
Local, regional, and distal control of the disease at 3 years
3 - 60 Months Yes
See also
  Status Clinical Trial Phase
Completed NCT00764829 - Blood Samples to Evaluate Biomarkers of Donor Chimerism N/A
Terminated NCT01500161 - Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match Phase 2
Completed NCT00901225 - Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant Phase 2
Completed NCT02639559 - Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies Phase 2
Completed NCT00697684 - Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant Phase 1
Completed NCT00802113 - Autologous and Allogeneic Transplant for Relapsed Lymphoma Phase 1/Phase 2
Completed NCT01951885 - Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention Phase 3
Completed NCT00754286 - A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer N/A
Completed NCT00364676 - Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease Phase 1
Completed NCT00571662 - Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant Phase 2
Completed NCT00713882 - Health and Psychosocial Outcomes in Long-Term Lymphoma Survivors N/A